1.
Int J Clin Pharmacol Ther
; 59(6): 467-470, 2021 Jun.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33605877
RESUMEN
Imatinib, a tyrosine kinase inhibitor, is frequently used to treat unresectable or metastatic gastrointestinal stromal tumors. The application of this medication is considered an adjuvant treatment of gastrointestinal stromal tumors. It can reduce the postoperative recurrence of the tumors. During the treatment with imatinib, there can be various gastrointestinal adverse reactions, which are mild and can be alleviated following a reduction in the dose. It is rare that perforation of the digestive tract happens after the employment of this medication. This study reported that imatinib mesylate caused bowel perforation in one patient with gastric stromal tumors after its use for 3 months.
Asunto(s)
Antineoplásicos , Tumores del Estroma Gastrointestinal , Antineoplásicos/efectos adversos , Benzamidas/efectos adversos , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Tumores del Estroma Gastrointestinal/cirugía , Humanos , Mesilato de Imatinib/efectos adversos , Recurrencia Local de Neoplasia , Piperazinas/efectos adversos , Pirimidinas/efectos adversos
2.
Hepatobiliary Pancreat Dis Int
; 19(5): 495-498, 2020 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-31753597